7 October 2020 - Bristol Myers Squibb's medication provides a new oral treatment option for Canadians living with the neurological disease.
Bristol Myers Squibb announced today that Health Canada approved Zeposia (ozanimod) for the treatment of patients with relapsing remitting multiple sclerosis to decrease the frequency of clinical exacerbations.
The Health Canada approval is based on data from the randomised, active-controlled Phase 3 SUNBEAM and RADIANCE Part B clinical trials, which enrolled more than 2,600 patients across 150 sites in more than 20 countries.